Brief: Abivax Announces Acceptance Of Phase 3 Induction Trials
29/09/2025 23:21
Sept 29 (Reuters) - Abivax SA ABVX.PA: ABIVAX ANNOUNCES ACCEPTANCE OF ADDITIONAL LATE-BREAKING ABSTRACT FROM THE ABTECT PHASE 3 INDUCTION TRIALS TO BE PRESENTED AT 2025 UNITED EUROPEAN GASTROENTEROLOGY (UEG) MEETING Source text: ID:nGNX70BD0S Further company coverage: ABVX.PA (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Abivax SA
See all newsAbivax shares fall after rival drug data, trader says
France's Abivax H1 net loss widens on higher expenses driven by clinical programs
U.S. RESEARCH ROUNDUP-Caseys General Stores, Targa Resources, United Rentals
GS starts Abivax at 'buy,' sees multibillion sales potential for lead drug candidate
Europe's STOXX 600 ends week at all-time high on earnings support, soft US jobs data